ATE334145T1 - Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen - Google Patents

Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen

Info

Publication number
ATE334145T1
ATE334145T1 AT01911811T AT01911811T ATE334145T1 AT E334145 T1 ATE334145 T1 AT E334145T1 AT 01911811 T AT01911811 T AT 01911811T AT 01911811 T AT01911811 T AT 01911811T AT E334145 T1 ATE334145 T1 AT E334145T1
Authority
AT
Austria
Prior art keywords
cancer
new human
paraneoplastic syndrome
diagnostic treatment
polypeptide
Prior art date
Application number
AT01911811T
Other languages
German (de)
English (en)
Inventor
Michele Aguera
Jean-Christophe Antoine
Marie-Francoise Belin
Jerome Honnorat
Veronique Rogemont
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26212215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE334145(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0002566A external-priority patent/FR2805540B1/fr
Priority claimed from FR0005005A external-priority patent/FR2807757B1/fr
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE334145T1 publication Critical patent/ATE334145T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
AT01911811T 2000-02-29 2001-02-28 Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen ATE334145T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002566A FR2805540B1 (fr) 2000-02-29 2000-02-29 Nouvelle proteine ulip humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
FR0005005A FR2807757B1 (fr) 2000-04-18 2000-04-18 Nouvelle proteine ulip/crmp humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques et paraneoplastiques

Publications (1)

Publication Number Publication Date
ATE334145T1 true ATE334145T1 (de) 2006-08-15

Family

ID=26212215

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01911811T ATE334145T1 (de) 2000-02-29 2001-02-28 Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen

Country Status (8)

Country Link
US (4) US7329499B2 (ja)
EP (1) EP1263784B1 (ja)
JP (1) JP4990459B2 (ja)
AT (1) ATE334145T1 (ja)
CA (1) CA2401438C (ja)
DE (2) DE60121735T4 (ja)
ES (1) ES2269353T3 (ja)
WO (1) WO2001064737A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002620A2 (en) * 2000-06-29 2002-01-10 Mayo Foundation For Medical Education And Research Crmp-5 (collapsin response-mediator protein) encoding nucleic acid, polypeptide and uses thereof
DE102009033281B4 (de) 2009-07-15 2018-12-13 Euroimmun Medizinische Labordiagnostika Ag Verfahren zur Detektion von Autoantikörpern bei paraneoplastischen neurologischen Syndromen
WO2020154654A1 (en) * 2019-01-25 2020-07-30 Mayo Foundation For Medical Education And Research Assessing and treating germ cell tumors and paraneoplastic autoimmunity
WO2021048263A1 (en) 2019-09-13 2021-03-18 Euroimmun Medizinische Labordiagnostika Ag Improved detection of nmda receptor autoantibodies
CN112270684B (zh) * 2020-12-25 2021-04-06 宁波兰茜生物科技有限公司 一种显微图像免疫组化虚拟多重标记及分析方法及系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759701B1 (fr) * 1997-02-19 1999-06-04 Inst Nat Sante Rech Med Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
AU2001241511A1 (en) * 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
US20050175607A1 (en) * 2000-02-28 2005-08-11 Tang Y T. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
US20190119339A1 (en) 2019-04-25
US10087220B2 (en) 2018-10-02
US20130243755A1 (en) 2013-09-19
ES2269353T3 (es) 2007-04-01
CA2401438C (fr) 2011-11-29
US8377645B2 (en) 2013-02-19
EP1263784A1 (fr) 2002-12-11
US20080226636A1 (en) 2008-09-18
DE60121735T2 (de) 2007-08-30
DE60121735T4 (de) 2010-07-08
JP2003525059A (ja) 2003-08-26
JP4990459B2 (ja) 2012-08-01
EP1263784B1 (fr) 2006-07-26
DE60121735D1 (de) 2006-09-07
CA2401438A1 (fr) 2001-09-07
WO2001064737A1 (fr) 2001-09-07
US20030176336A1 (en) 2003-09-18
US7329499B2 (en) 2008-02-12

Similar Documents

Publication Publication Date Title
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
DK0458878T3 (da) Nyt monoklonalt antistof mod et nyt antigen, der er associeret med humane tumorer
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
RU2001126052A (ru) Моноклональные антитела, антигены и их применение для диагностики и терапии злокачественных заболеваний
HRP20100412T1 (hr) Identifikacija površinskih antigena radi dijagnoze i liječenja tumora
WO2001059064A3 (en) Nucleic acids, proteins, and antibodies
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE60028544D1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
RU95118411A (ru) Гибридная клеточная линия (варианты), препарат антител (варианты), способ диагностики рассеянного склероза у человека (варианты) способ лечения человека, полипептид
DE69735020D1 (de) Verfahren zur Diagnose von Prostatakrebs
ATE547523T1 (de) Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden
ATE463508T1 (de) Reagentien und verfahren zur erkennung von erkrankungen der brust
ATE334145T1 (de) Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen
DE60026733D1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
JP2007530420A5 (ja)
EP0834568A3 (en) Novel saliva binding protein
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
DE69939379D1 (de) Hemmstoff zur diagnose und behandlung von haemophilia a patienten
PT629238E (pt) Autotaxina: proteina estimuladora da motilidade util no diagnostico e tarapia do cancro
ES2355265T3 (es) Un kit para detección inmunologica de nuroglobulina ligada a enzima y uso del mismo.
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties